Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
aTyr Pharma, Inc.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Confirmation of SARS-CoV-2 infection by polymerase chain reaction (PCR).
Severe pneumonia related to SARS-CoV-2 infection, defined as fever or suspected respiratory infection with radiographic abnormalities suggestive of viral pneumonia, plus at least 1 of the following:
* Respiratory rate \>30 breaths/minute;
* Severe respiratory distress, as determined by the Investigator;
* Oxygen saturation (SpO2) ≤93% on room air.
You may not be if
Participant is intubated/mechanically ventilated.
In the opinion of the Investigator, participant's progression to death is imminent.
Treatment with immunosuppressant/immunotherapy drugs, including but not limited to interleukin (IL)-6 inhibitors, tumor necrosis factor-alpha (TNF-α) inhibitors, anti-IL-1 agents and janus kinase inhibitors within 5 half-lives or 30 days prior to Day 1.
Use of chronic (\>30 days) oral corticosteroids for a non-COVID-19-related condition in a dose higher than prednisone 10 mg or equivalent per day.
Weight \>165 kg or \<40 kg.
Clareo Health | Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19
